Evidence map›Paper›PMID 40987773›Full record

ArticleNature communications2025

PBK/TOPK mediates Ikaros, Aiolos and CTCF displacement from mitotic chromosomes and alters chromatin accessibility at selected C2H2-zinc finger protein binding sites.

Andrew Dimond, Do Hyeon Gim, Elizabeth Ing-Simmons, Chad Whilding, Holger B Kramer, Dounia Djeghloul, Alex Montoya, Bhavik Patel, Sherry Cheriyamkunnel, Karen E Brown and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Andrew DimondEpigenetic Memory Group, MRC LMS, Imperial College London, Hammersmith Hospital Campus, London, UK. andrew.dimond@bioch.ox.ac.uk.ORCID http://orcid.org/0000-0002-2996-2479
Do Hyeon GimEpigenetic Memory Group, MRC LMS, Imperial College London, Hammersmith Hospital Campus, London, UK.ORCID http://orcid.org/0009-0008-0907-8310
Elizabeth Ing-SimmonsDevelopmental Epigenomics Group, MRC LMS, Imperial College London, Hammersmith Hospital Campus, London, UK.ORCID http://orcid.org/0000-0002-0394-2429
Chad WhildingMicroscopy Facility, MRC LMS, Imperial College London, Hammersmith Hospital Campus, London, UK.
Holger B KramerMass Spectrometry Facility, MRC LMB, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, UK.
Dounia DjeghloulEpigenetic Memory Group, MRC LMS, Imperial College London, Hammersmith Hospital Campus, London, UK.ORCID http://orcid.org/0000-0002-7914-9777
Alex MontoyaProteomics and Metabolomics Facility, MRC LMS, Imperial College London, Hammersmith Hospital Campus, London, UK.ORCID http://orcid.org/0000-0002-6501-883X
Bhavik PatelFlow Cytometry Facility, MRC LMS, Imperial College London, Hammersmith Hospital Campus, London, UK.
Sherry CheriyamkunnelEpigenetic Memory Group, MRC LMS, Imperial College London, Hammersmith Hospital Campus, London, UK.
Karen E BrownEpigenetic Memory Group, MRC LMS, Imperial College London, Hammersmith Hospital Campus, London, UK.
Pavel V ShliahaProteomics and Metabolomics Facility, MRC LMS, Imperial College London, Hammersmith Hospital Campus, London, UK.ORCID http://orcid.org/0000-0003-3092-0724
Juan M VaquerizasDevelopmental Epigenomics Group, MRC LMS, Imperial College London, Hammersmith Hospital Campus, London, UK.ORCID http://orcid.org/0000-0002-6583-6541
Matthias MerkenschlagerLymphocyte Development Group, MRC LMS, Imperial College London, Hammersmith Hospital Campus, London, UK.ORCID http://orcid.org/0000-0003-2889-3288
Amanda G FisherEpigenetic Memory Group, MRC LMS, Imperial College London, Hammersmith Hospital Campus, London, UK. amanda.fisher@bioch.ox.ac.uk.ORCID http://orcid.org/0000-0003-3010-3644

Funding

Kay Kendall Leukaemia Fund (KKLF) KKL1334RCUK | Medical Research Council (MRC) MC_PC_23024RCUK | Medical Research Council (MRC) MC_UP_1605/11Wellcome TrustWellcome Trust (Wellcome) WCMA_PSN102
6 · The paper itself

Abstract

PBK/TOPK is a mitotic kinase implicated in haematological and non-haematological cancers. Here we show that the key haemopoietic regulators Ikaros and Aiolos require PBK-mediated phosphorylation to dissociate from chromosomes in mitosis. Eviction of Ikaros is rapidly reversed by addition of the PBK-inhibitor OTS514, revealing dynamic regulation by kinase and phosphatase activities. To identify more PBK targets, we analysed loss of mitotic phosphorylation events in Pbk

Indexed as

CCCTC-Binding FactorChromatinIkaros Transcription FactorMitosisAnimalsBinding SitesDNA-Binding ProteinsHumansMicePhosphorylationProtein BindingTranscription FactorsZinc FingersCCCTC-Binding FactorChromatinCTCF protein, humanDNA-Binding ProteinsIkaros Transcription FactorIKZF1 protein, humanIKZF3 protein, humanTranscription Factors

Identifiers

PMID40987773
PMCPMC12457614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.